SLN Brain Targeting Drug Delivery for Cns: A Novel Approach

Abstract

The brain is a delicate organ and nature has very efficiently protected it. Brain is protected by presence of two barrier systems BBB (Blood Brain Barrier) and BCSFB (Blood Cerebrospinal Fluid Barrier) from very harmful materials. Despite aggressive research, patients suffering from fatal or debilitatingcentral nervous system (CNS) diseases, such as brain tumours, HIV encephalopathy, epilepsy, cerebrovascular diseases and neurodegenerative disorders, clinical failure of it restricts the passive diffusion of many drugs into the brain and constitutes a significant obstacle in pharmacological treatment of CNS disorders. Various strategies like non-invasive methods, including drug manipulation encompassing transformation into lipophilic analogues, pro-drugs, chemical mediated, carrier-mediated, vector mediated and intranasal mediated drug delivery. 'SLN technology based therapy' made available a novel and sound platform for therapeutics. Solid lipid nanoparticles (SLNs) are structured for a novel system to provide drugs for removal of unwanted actions by modified formulations and for organ/cell targeting of moieties. Appropriate analytical techniques for the characterization of SLN is described hear. This article contains method of preparation, utilization of excipients(s), uses and highlighting of various approaches and meritsof SLN for brain targeting drug delivery as colloidal drug carriers.

Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles

“…They are easily biocompatible and biodegradable, capable of protecting labile activities against degradation and enhance their stability. SLN is beneficial in targeting the chemotherapy in mitosis when the amounts of drug present in tumour tissue were required to maintain for a long duration [27]. Gupta et al developed the SLN of efavirenz [28] to target the drug to the brain via the intranasal route.…”